Unresectable Malignant Neoplasm: Clinical Trials

9 trials for Unresectable Malignant Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 3, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 23Recruiting 1, Unknown 1, Withdrawn 1

Follow Unresectable Malignant Neoplasm: new trials by email Literature Review of Unresectable Malignant Neoplasm trials Research Report on Unresectable Malignant Neoplasm

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chemoradiotherapy in Unresectable Esophageal Cancer
Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy
Phase 1 / Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1052019-10-012024-12-13
ImmunoPET With an Anti-CD8 Imaging Agent
Anti-CD8 PET imaging agent - Metastatic Cancer, Unresectable Malignant Neoplasm
Phase 1 / Phase 2UnknownUniversity Medical Center Groningen472019-02-142024-05-03
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-08-312025-02-21
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Axatilimab, Durvalumab - Solid Tumor, Metastatic Tumor
Phase 1CompletedSyndax Pharmaceuticals452017-09-012024-05-17
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
18F-FHBG, Aldesleukin, Busulfan - HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm
Phase 1TerminatedJonsson Comprehensive Cancer Center52017-07-262023-11-01
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Phase 1CompletedWake Forest University Health Sciences242016-03-012023-06-05
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
Ilorasertib, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm, Solid Neoplasm
Phase 1CompletedUniversity of Chicago122015-09-082019-04-22
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
Sodium Bicarbonate - Tumor, Cancer
Phase 1TerminatedH. Lee Moffitt Cancer Center and Research Institute92013-09-012015-06-04
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Carcinoma of Unknown Primary
Phase 1Active not recruitingNational Cancer Institute (NCI)942011-06-202026-11-12

Narrower conditions

Neoplasm Metastasis (6)  ·  Esophageal Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Cancer Pain (1)  ·  Carcinoma, Transitional Cell (1)  ·  Chordoma (1)  ·  Endometrial Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Liver Failure (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)

Broader conditions

Neoplasms (8)  ·  Neoplastic Processes (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms by Site (3)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Esophageal Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Adnexal Diseases (1)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)

Interventions

130-nm albumin-bound paclitaxel (1)  ·  9-(4-fluoro-3-hydroxymethylbutyl)guanine (1)  ·  ALT-803 (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Busulfan (1)  ·  Carboplatin (1)  ·  Cell- and Tissue-Based Therapy (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Leukapheresis (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Paclitaxel (1)

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  ImmunityBio, Inc. (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Syndax Pharmaceuticals (1)  ·  University Medical Center Groningen (1)  ·  University of Chicago (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (7)  ·  China (1)  ·  Netherlands (1)

Top investigators

Amit Mahipal, M.D. (1)  ·  E. G.E. de Vries, MD, PhD (1)  ·  Heidi Klepin (1)  ·  Hussein A Tawbi (1)  ·  Kate Madigan, MD (1)  ·  Manish Sharma (1)  ·  Theodore Scott Nowicki, M.D. (1)  ·  Xin Wang, MD (1)

Results publications

PMID 33867481, PMID 36271158, PMID 36452492, PMID 36471036, PMID 39704205, PMID 40593578

NIH funding

N01CM00100 (1), P30CA012197 (1), P30CA014599 (1), P30CA047904 (1), U01CA062490 (1), U01CA062502 (1), U01CA062505 (1), U01CA069856 (1), U01CA070095 (1), U01CA099168 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA186717 (1)